0000899243-16-028189.txt : 20160829
0000899243-16-028189.hdr.sgml : 20160829
20160829163122
ACCESSION NUMBER: 0000899243-16-028189
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160825
FILED AS OF DATE: 20160829
DATE AS OF CHANGE: 20160829
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hooks Corwin Dale
CENTRAL INDEX KEY: 0001665347
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 161858176
MAIL ADDRESS:
STREET 1: C/O CLOVIS ONCOLOGY, INC.
STREET 2: 5500 FLATIRON PARKWAY
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-08-25
0
0001466301
Clovis Oncology, Inc.
CLVS
0001665347
Hooks Corwin Dale
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY
BOULDER
CO
80301
0
1
0
0
See Remarks
Stock Option (right to buy)
22.73
2016-08-25
4
A
0
27800
0.00
A
2026-08-25
Common Stock
27800
27800
D
Restricted Stock Units
2016-08-25
4
A
0
13900
0.00
A
Common Stock
13900
13900
D
Stock Option (right to buy)
20.90
2026-02-01
Common Stock
10000
10000
D
Stock Option (right to buy)
19.37
2026-03-01
Common Stock
10000
10000
D
The option shall vest as to 25% of the shares on August 25, 2017, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
Each restricted stock unit represents the right to receive one share of Common Stock.
The restricted stock units shall vest as to 25% of the units on August 25, 2017, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
The option shall vest as to 25% of the shares on February 1, 2017, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
The vesting schedule for this option was incorrectly reported on a previously filed Form 4. This Form 4 reflects the correct vesting schedule.
The option shall vest as to 25% of the shares on March 1, 2017, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
Senior Vice President and Chief Commercial Officer
/s/ Corwin Dale Hooks
2016-08-29